Association between liver targeted antiviral therapy in colorectal cancer and survival benefits: An appraisal

doi:10.12998/wjcc.v8.i11.2111

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 11

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7942)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

421

WORD

139

HTML

3833

Tables (1-1)

607

Sum=5000

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1003

Download

1939

Sum=2942

Jun 6, 2020 (publication date) through Mar 1, 2026

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Clin Cases. Jun 6, 2020; 8(11): 2111-2115
Published online Jun 6, 2020. doi: 10.12998/wjcc.v8.i11.2111

Association between liver targeted antiviral therapy in colorectal cancer and survival benefits: An appraisal

Qiang Wang, Chao-Ran Yu

Qiang Wang, Chao-Ran Yu, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Shanghai 200025, China

Author contributions: Wang Q and Yu CR designed the research; Wang Q prepared the literature review and wrote the paper; Yu CR coordinated the reference review and performed the majority of the writing.

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors who contributed their efforts in this manuscript.

Corresponding author: Chao-Ran Yu, MD, PhD, Surgeon, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, 270 Dongan Road, Shanghai 200025, China. chaoran_yu@yeah.net

Received: March 7, 2020
Peer-review started: March 7, 2020
First decision: March 24, 2020
Revised: April 10, 2020
Accepted: May 1, 2020
Article in press: May 1, 2020
Published online: June 6, 2020
Processing time: 93 Days and 3.1 Hours

Abstract

In colorectal cancer (CRC), liver metastasis remains a major contributor to the cause of cancer-related death. Putative biomarkers, therapeutic efficacy, and drug insensitivity still pose clinical challenges for metastatic CRC patients. Interestingly, previous studies indicated that tumor cells in CRC did not metastasize to the injured liver, which included hepatitis or cirrhotic liver. The benefits of antiviral therapy on hepatocellular carcinoma have also been identified. This review discusses the role of antiviral therapy on the liver. Antiviral therapy may reduce potential liver metastasis associated with CRC in several mechanistic aspects.

Keywords: Colorectal cancer; Liver metastasis; Antiviral therapy; Survival; Injury status; Biomarkers

Core tip: Liver metastasis is one of the major contributors to the cancer-related deaths in colorectal cancer. Previous studies reported that tumor cells rarely metastasize to the injured liver during the disease course. Others also identified survival benefits brought by antiviral therapy upon hepatocellular carcinoma. Hereby, this review discusses the potential impact of antiviral therapy in reducing liver metastasis of colorectal cancer.